A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Phase of Trial: Phase III
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 29 Nov 2018 Study design has been changed from parallel to crossover and number of treatment arms has also changed from 4 to 5.
- 29 Nov 2018 Planned End Date changed from 31 Mar 2019 to 31 Aug 2019.
- 29 Nov 2018 Status changed from active, no longer recruiting to recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History